JoAnn Pinkerton, MD: Elinzanetant is a dual neurokinin receptor inhibitor. It's an NK1 and NK3 receptor antagonist, and what ...
OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and ...
Women who reported more frequent physical activity experienced significantly lower perimenopause symptom burden across ...
Pauline Maki, PhD, discusses real-world OPTION-VMS data linking fezolinetant to improvements in menopausal VMS, depression, ...
Women receiving menopause hormone therapy (HT) alongside semaglutide experienced significantly greater weight loss than those ...
Women with moderate to severe vasomotor symptoms (VMS) who received elinzanetant (Lynkuet; Bayer) were more likely than those ...
Women who reached menopause before age 40 years had a higher long-term risk of cardiovascular disease (CVD) and coronary ...
CBT is an evidence-based, nonhormonal option endorsed by the National Institutes of Health and The Menopause Society for ...
Capsule-sponge DNA methylation test boosts Barrett’s screening access, showing high accuracy, strong tolerability, and ...
Pauline M. Maki, PhD, reviews the first data cuts from OPTION-VMS, released at The Menopause Society 2025 meeting. These ...
Pauline M. Maki, PhD, introduces OPTION-VMS and explains why real-world data are needed to test whether randomized trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results